论文部分内容阅读
目的:评价奈达铂联合氟脲嘧啶/四氢叶酸治疗晚期复发耐药食管癌的疗效及不良反应。方法:30例晚期复发耐药食管癌均经病理学或细胞学确诊。奈达铂100 mg/m2,静脉滴注,第1天;氟脲嘧啶500 mg/m2,静脉滴注,维持6~8小时,第1~5天;四氢叶酸200 mg,静脉滴注,第1~5天,21天为一周期,连续用2周期后评价疗效及不良反应。结果:30例均完成2个周期以上化疗,共接受86周期化疗,全部病例均可评价疗效及不良反应。无CR病例,PR 13例(43.3%),SD 7例(23.3%),PD 10例(33.3%),有效率为43.3%,TTP 4.0月,MST8.3月。不良反应主要是骨髓抑制,恶心、呕吐,全组无IV度不良反应。结论:奈达铂联合氟脲嘧啶/四氢叶酸治疗晚期复发耐药食管癌有确切疗效,不良反应轻,耐受性好,值得临床进一步推广应用。
Objective: To evaluate the efficacy and adverse reactions of Nedaplatin plus fluorouracil / tetrahydrofolate in the treatment of advanced recurrent esophageal cancer. Methods: Thirty patients with recurrent esophageal cancer were confirmed by pathology or cytology. Nedaplatin 100 mg / m2, intravenous infusion, on the first day; fluorouracil 500 mg / m2, intravenous infusion, maintaining 6 to 8 hours, 1 to 5 days; tetrahydrofolate 200 mg, intravenous drip, The first to fifth days, 21 days for a period of two weeks after the continuous evaluation of efficacy and adverse reactions. Results: All of the 30 patients completed more than 2 cycles of chemotherapy, and received 86 cycles of chemotherapy. All patients were able to evaluate the efficacy and adverse reactions. In the absence of CR, 13 (43.3%) were PR, 7 (23.3%) were SD, and 10 (33.3%) were PD with an effective rate of 43.3%, TTP 4.0, MST 8. 3 months. Adverse reactions are mainly myelosuppression, nausea, vomiting, the whole group without IV adverse reactions. Conclusion: Nedaplatin combined with fluorouracil / tetrahydrofolate is effective in the treatment of advanced recurrent esophageal cancer, with mild adverse reactions and good tolerability. It is worth further clinical application.